Core Insights - In 2025, China approved a record 76 innovative drugs, significantly surpassing the 48 approved in 2024, marking a historical high [1] - The total value of innovative drug licensing transactions in China exceeded $130 billion in 2025, with over 150 transactions, also setting a new record [1] Group 1: Drug Approvals - The 76 approved innovative drugs in 2025 include 47 chemical drugs, 23 biological products, and 6 traditional Chinese medicines [1] - Among the 47 chemical drugs, 38 are domestically developed, accounting for 80.85% of the total [1] - For the 23 biological products, 21 are domestic innovations, representing 91.30% of the total [1] Group 2: First-in-Class Drugs - In 2025, 11 first-in-class innovative drugs were approved, with 4 being independently developed in China [1] Group 3: Licensing Transactions - The innovative drug licensing transactions in 2025 exceeded $130 billion, compared to $51.9 billion in 2024, indicating a substantial increase [1] - The number of licensing transactions rose from 94 in 2024 to over 150 in 2025 [1] Group 4: Future Initiatives - Starting in 2026, the National Medical Products Administration (NMPA) plans to implement more measures to accelerate the development of innovative drugs in China [2]
创新高！2025年我国批准创新药76个 对外授权破千亿美元
Yang Shi Xin Wen·2026-01-03 08:18